Dr. rer. nat. Franziska Gsottberger



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response (2023) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Journal article Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1a-Mediated Apoptosis Following Unfolded Protein Response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity (2022) Pelzl R, Kübel S, Klein P, Gsottberger F, Wendland K, Petkovic S, Brueckl V, et al. Conference contribution Targeted Inhibition of Protein Biosynthesis sensitizes Cancer Cells to IRE1a-mediated Apoptosis as a Consequence of the unfolded protein response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Human CD22-transgenic, primary murine lymphoma challenges immunotherapies in organ-specific tumor microenvironments (2021) Gsottberger F, Brandl C, Wendland K, Petkovic S, Emmerich C, Erber R, Geppert CI, et al. Journal article Synergy of simultaneous activation of cell death pathways of unfolded protein response and of protein synthesis inhibition converges at IRE1a-immunotoxins generate a therapeutic window (2021) Gsottberger F, Meier C, Ammon AM, Petkovic S, Mellenthin L, Krumbholz M, Metzler M, et al. Conference contribution Triton X-114 and Amine-Based Wash Strategy Reduces Lipopolysaccharides to FDA Limit and Achieves Purer, More Potent Recombinant Immunotoxin (2021) George R, Gsottberger F, Ammon AM, Wendland K, Mellenthin L, Mackensen A, Müller F Journal article A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment (2020) Gsottberger F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution Blocking counter regulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities (2020) Müller F, Gsottberger F, Meier C, Petkovic S, Krumbholz M, Metzler M, Mackensen A Conference contribution A human CD22 transgenic, myc-driven lymphoma model to test effects of targeted therapies on lymphoma immune microenvironment in immunecompetent mice (2019) Wagner F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution